Literature DB >> 28937318

The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells.

Hakan Kucuksayan1, Hakan Akca1.   

Abstract

Epithelial-mesenchymal transition is a crucial event for metastasis and could be mediated by several pathways such as phosphoinositide 3-kinase/Akt, mitogen-activated protein kinases, as well as many epigenetic regulators. Special AT-rich sequence-binding protein 2 is an epigenetic regulator involved in epithelial-mesenchymal transition and osteoblastic differentiation. It has been reported that the crosstalk between several pathways is responsible for the regulation of epithelial-mesenchymal transition in cancer cells. However, crosstalks between p38 and Akt pathways involved in epithelial-mesenchymal transition are still unknown. We recently reported that there is a crosstalk between p38 and Akt pathways in non-small-cell lung carcinoma cells, and this crosstalk is associated with E-cadherin and special AT-rich sequence-binding protein 2 expressions. Therefore, we aimed to determine whether this crosstalk has a mediator role in the regulation of epithelial-mesenchymal transition in non-small-cell lung carcinoma. Our results showed that inhibition of p38 leads to the disruption of this crosstalk via decreased expression of phosphatase and tensin homolog (PTEN) and subsequently increased activation of Akt in non-small-cell lung carcinoma cells. Then, we found that p38 inhibition upregulated special AT-rich sequence-binding protein 2 expression and reversed epithelial-mesenchymal transition in non-small-cell lung carcinoma cells. Furthermore, special AT-rich sequence-binding protein 2 knockdown abolished the effect of p38 inhibition on epithelial-mesenchymal transition in non-small-cell lung carcinoma cells. In conclusion, our results strongly indicate that the crosstalk between p38 and Akt pathways can determine special AT-rich sequence-binding protein 2 expression and epithelial character of non-small-cell lung carcinoma cells, and special AT-rich sequence-binding protein 2 is a critical epigenetic regulator for epithelial-mesenchymal transition mediated by p38 pathway in non-small-cell lung carcinoma. Our findings will contribute to illuminate the molecular mechanisms of the epithelial-mesenchymal transition process that has a critical significance for lung cancer metastasis.

Entities:  

Keywords:  Akt; SATB2; epithelial–mesenchymal transition; non-small-cell lung cancer; p38

Mesh:

Substances:

Year:  2017        PMID: 28937318     DOI: 10.1177/1010428317706212

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

Review 1.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

2.  Long non-coding RNA H19 promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by regulating microRNA-140-5p/SATB2 axis.

Authors:  H U Bi; Dong Wang; Xiaoyu Liu; Gang Wang; Xuejian Wu
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

Review 3.  Role of p38 MAP kinase in cancer stem cells and metastasis.

Authors:  Sriya Kudaravalli; Petra den Hollander; Sendurai A Mani
Journal:  Oncogene       Date:  2022-04-30       Impact factor: 8.756

Review 4.  Multiscale Regulation of the Intervertebral Disc: Achievements in Experimental, In Silico, and Regenerative Research.

Authors:  Laura Baumgartner; Karin Wuertz-Kozak; Christine L Le Maitre; Francis Wignall; Stephen M Richardson; Judith Hoyland; Carlos Ruiz Wills; Miguel A González Ballester; Michael Neidlin; Leonidas G Alexopoulos; Jérôme Noailly
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 5.  SATB2: A versatile transcriptional regulator of craniofacial and skeleton development, neurogenesis and tumorigenesis, and its applications in regenerative medicine.

Authors:  Xia Huang; Qiuman Chen; Wenping Luo; Mikhail Pakvasa; Yuxin Zhang; Liwen Zheng; Shuang Li; Zhuohui Yang; Huan Zeng; Fang Liang; Fugui Zhang; Daniel A Hu; Kevin H Qin; Eric J Wang; David S Qin; Russell R Reid; Tong-Chuan He; Aravind Athiviraham; Mostafa El Dafrawy; Hongmei Zhang
Journal:  Genes Dis       Date:  2020-10-17

6.  CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt-mediated protein synthesis and inhibition of apoptosis.

Authors:  Yusuke Mori; Ayaka Takeuchi; Kengo Miyagawa; Hiroyuki Yoda; Hiroaki Soda; Yoshihiro Nabeya; Naoko Watanabe; Toshinori Ozaki; Osamu Shimozato
Journal:  FEBS Open Bio       Date:  2021-03-28       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.